![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
School of Food Biosciences, The University of Reading, Whiteknights, Reading RG6 6AP, UK and * Institute of Food Research, Norwich Research Park, Colney, Norwich, NR4 7UA, UK
2To whom correspondence should be addressed. E-mail: g.tzortzis{at}reading.ac.uk.
Prebiotics are nondigestible food ingredients that encourage proliferation of selected groups of the colonic microflora, thereby altering the composition toward a more beneficial community. In the present study, the prebiotic potential of a novel galactooligosaccharide (GOS) mixture, produced by the activity of galactosyltransferases from Bifidobacterium bifidum 41171 on lactose, was assessed in vitro and in a parallel continuous randomized pig trial. In situ fluorescent hybridization with 16S rRNA-targeted probes was used to investigate changes in total bacteria, bifidobacteria, lactobacilli, bacteroides, and Clostridium histolyticum group in response to supplementing the novel GOS mixture. In a 3-stage continuous culture system, the bifidobacterial numbers for the first 2 vessels, which represented the proximal and traverse colon, increased (P < 0.05) after the addition of the oligosaccharide mixture. In addition, the oligosaccharide mixture strongly inhibited the attachment of enterohepatic Escherichia coli (P < 0.01) and Salmonella enterica serotype Typhimurium (P < 0.01) to HT29 cells. Addition of the novel mixture at 4% (wt:wt) to a commercial diet increased the density of bifidobacteria (P < 0.001) and the acetate concentration (P < 0.001), and decreased the pH (P < 0.001) compared with the control diet and the control diet supplemented with inulin, suggesting a great prebiotic potential for the novel oligosaccharide mixture.
KEY WORDS: • intestinal microflora • prebiotic • galactooligosaccharides
This article has been cited by other articles:
|
|
 |
|
  L. E. J. Searle, A. Best, A. Nunez, F. J. Salguero, L. Johnson, U. Weyer, A. H. Dugdale, W. A. Cooley, B. Carter, G. Jones, et al. A mixture containing galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice J. Med. Microbiol., January 1, 2009; 58(1): 37 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vulevic, A. Drakoularakou, P. Yaqoob, G. Tzortzis, and G. R Gibson Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1438 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Depeint, G. Tzortzis, J. Vulevic, K. I'Anson, and G. R Gibson Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study Am. J. Clinical Nutrition, March 1, 2008; 87(3): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Amaretti, T. Bernardi, E. Tamburini, S. Zanoni, M. Lomma, D. Matteuzzi, and M. Rossi Kinetics and Metabolism of Bifidobacterium adolescentis MB 239 Growing on Glucose, Galactose, Lactose, and Galactooligosaccharides Appl. Envir. Microbiol., June 1, 2007; 73(11): 3637 - 3644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Loh, M. Eberhard, R. M. Brunner, U. Hennig, S. Kuhla, B. Kleessen, and C. C. Metges Inulin Alters the Intestinal Microbiota and Short-Chain Fatty Acid Concentrations in Growing Pigs Regardless of Their Basal Diet J. Nutr., May 1, 2006; 136(5): 1198 - 1202. [Abstract] [Full Text] [PDF]
|
|
